Literature DB >> 23517714

Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders.

Kay B Barnes1, Jackie Steward, Joanne E Thwaite, M Stephen Lever, Carwyn H Davies, Stuart J Armstrong, Thomas R Laws, Neil Roughley, Sarah V Harding, Timothy P Atkins, Andrew J H Simpson, Helen S Atkins.   

Abstract

Burkholderia pseudomallei is the causative agent of the disease melioidosis, which is prevalent in tropical countries and is intractable to a number of antibiotics. In this study, the antibiotic co-trimoxazole (trimethoprim/sulfamethoxazole) was assessed for the post-exposure prophylaxis of experimental infection in mice with B. pseudomallei and its close phylogenetic relative Burkholderia mallei, the causative agent of glanders. Co-trimoxazole was effective against an inhalational infection with B. pseudomallei or B. mallei. However, oral co-trimoxazole delivered twice daily did not eradicate infection when administered from 6h post exposure for 14 days or 21 days, since infected and antibiotic-treated mice succumbed to infection following relapse or immunosuppression. These data highlight the utility of co-trimoxazole for prophylaxis both of B. pseudomallei and B. mallei and the need for new approaches for the treatment of persistent bacterial infection. Crown
Copyright © 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23517714     DOI: 10.1016/j.ijantimicag.2013.02.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  Efficacy of postexposure therapy against glanders in mice.

Authors:  David M Waag
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 3.  Emerging role of biologics for the treatment of melioidosis and glanders.

Authors:  Daniel Tapia; Javier I Sanchez-Villamil; Alfredo G Torres
Journal:  Expert Opin Biol Ther       Date:  2019-10-15       Impact factor: 4.388

4.  Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection.

Authors:  Shane Massey; Linsey A Yeager; Carla A Blumentritt; Sudhamathi Vijayakumar; Elena Sbrana; Johnny W Peterson; Trevor Brasel; James W LeDuc; Janice J Endsley; Alfredo G Torres
Journal:  Sci Rep       Date:  2014-03-07       Impact factor: 4.379

Review 5.  Treatment and prophylaxis of melioidosis.

Authors:  David Dance
Journal:  Int J Antimicrob Agents       Date:  2014-02-03       Impact factor: 5.283

6.  Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory-a Response from the Front Line.

Authors:  David A B Dance; Direk Limmathurotsakul; Bart J Currie
Journal:  J Clin Microbiol       Date:  2017-03       Impact factor: 5.948

7.  Layered and integrated medical countermeasures against Burkholderia pseudomallei infections in C57BL/6 mice.

Authors:  Christopher P Klimko; Jennifer L Shoe; Nathaniel O Rill; Melissa Hunter; Jennifer L Dankmeyer; Yuli Talyansky; Lindsey K Schmidt; Caitlyn E Orne; David P Fetterer; Sergei S Biryukov; Mary N Burtnick; Paul J Brett; David DeShazer; Christopher K Cote
Journal:  Front Microbiol       Date:  2022-08-17       Impact factor: 6.064

8.  Use of a safe, reproducible, and rapid aerosol delivery method to study infection by Burkholderia pseudomallei and Burkholderia mallei in mice.

Authors:  Eric R Lafontaine; Shawn M Zimmerman; Teresa L Shaffer; Frank Michel; Xiudan Gao; Robert J Hogan
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

9.  Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.

Authors:  Kay B Barnes; Karleigh A Hamblin; Mark I Richards; Thomas R Laws; Andreas Vente; Helen S Atkins; Sarah V Harding
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.